3-(3-异丙基-1,2,4-氧杂二唑-5-基)哌啶1HCL | 902837-19-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 3-(3-异丙基-1,2,4-氧杂二唑-5-基)哌啶1HCL
• 中文别名: 3-(3-异丙基-1,2,4-二唑-5-基)哌啶
• 英文名称: 3-isopropyl-5-(piperidin-3-yl)-1,2,4-oxadiazole
• 英文别名: 3-(3-Isopropyl-1,2,4-oxadiazol-5-YL)piperidine；5-piperidin-3-yl-3-propan-2-yl-1,2,4-oxadiazole
• CAS: 902837-19-8
• 化学式: C₁₀H₁₇N₃O
• 分子量: 195.264
• InChiKey: RQHLIISYGVVOMZ-UHFFFAOYSA-N

物化性质

• 沸点：
  316.9±52.0 °C(Predicted)
• 密度：
  1.049±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  51
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (E)-3-(4-chloro-2-((5-methyl-2H-tetrazol-2-yl)methyl)phenyl)acrylic acid 、 3-(3-异丙基-1,2,4-氧杂二唑-5-基)哌啶1HCL 在 1-丙基磷酸酐 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 (rac)-(E)-3-(4-chloro-2-((5-methyl-2H-tetrazol-2-yl)methyl)phenyl)-1-(3-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl)prop-2-en-1-one
  参考文献：
  名称：

  [EN] AUTOTAXIN INHIBITORS COMPRISING A HETEROAROMATIC RING-BENZYL-AMIDE-CYCLE CORE
  [FR] INHIBITEURS DE L'AUTOTAXINE CONTENANT UN NOYAU À CYCLE BENZYLE-AMIDE CYCLIQUE HÉTÉROAROMATIQUE

  摘要：

  本发明涉及新型化合物，这些化合物是自体磷脂酶抑制剂，涉及它们的制备方法，含有它们的药物组合物和药物，以及它们在由自体磷脂酶介导的疾病和紊乱中的应用。

  公开号：

  WO2015008230A1

文献信息

• [EN] NOVEL VIRAL REPLICATION INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE RÉPLICATION VIRALE
  申请人：UNIV LEUVEN KATH

  公开号：WO2011015641A1

  公开（公告）日：2011-02-10

  The present invention relates to a series of novel compounds having antiviral activity, more specifically HIV (Human Immunodeficiency Virus) replication inhibiting properties. The invention also relates to methods for the preparation of such compounds, as well as to novel intermediates useful in one or more steps of such syntheses. The invention also relates to pharmaceutical compositions comprising an effective amount of such compounds as active ingredients. This invention further relates to the use of such compounds as medicines or in the manufacture of a medicament useful for the treatment of animals suffering from viral infections, in particular HIV infection. This invention further relates to methods for the treatment of viral infections in animals by the administration of a therapeutical amount of such compounds, optionally combined with one or more other drugs having antiviral activity.

  本发明涉及一系列具有抗病毒活性的新化合物，更具体地说是具有抑制HIV（人类免疫缺陷病毒）复制的特性。该发明还涉及制备这些化合物的方法，以及在这些合成步骤中使用的新中间体。该发明还涉及包含这些化合物作为活性成分的有效量的药物组合物。本发明进一步涉及将这些化合物用作药物或用于制造对患有病毒感染，特别是HIV感染的动物进行治疗的药物。本发明还涉及通过给动物投予这些化合物的治疗量，可选择地与具有抗病毒活性的一个或多个其他药物结合的方法来治疗动物的病毒感染。
• NOVEL VIRAL REPLICATION INHIBITORS
  申请人：Chaltin Patrick

  公开号：US20120129840A1

  公开（公告）日：2012-05-24

  The present invention relates to a series of novel compounds having antiviral activity, more specifically HIV (Human Immunodeficiency Virus) replication inhibiting properties. The invention also relates to methods for the preparation of such compounds, as well as to novel intermediates useful in one or more steps of such syntheses. The invention also relates to pharmaceutical compositions comprising an effective amount of such compounds as active ingredients. This invention further relates to the use of such compounds as medicines or in the manufacture of a medicament useful for the treatment of animals suffering from viral infections, in particular HIV infection. This invention further relates to methods for the treatment of viral infections in animals by the administration of a therapeutical amount of such compounds, optionally combined with one or more other drugs having antiviral activity.

  本发明涉及一系列具有抗病毒活性的新化合物，更具体地说是具有抑制HIV（人类免疫缺陷病毒）复制的特性。本发明还涉及制备这些化合物的方法，以及在这些合成的一个或多个步骤中有用的新中间体。本发明还涉及包含有效量这些化合物作为活性成分的药物组合物。本发明还涉及将这些化合物用作药物或制造用于治疗患有病毒感染的动物，特别是HIV感染的药物的用途。本发明还涉及通过给动物施用治疗量这些化合物的方法，可选地结合一种或多种具有抗病毒活性的其他药物，治疗动物的病毒感染。
• Viral replication inhibitors
  申请人：Chaltin Patrick

  公开号：US08906906B2

  公开（公告）日：2014-12-09

  The present invention relates to a series of novel compounds having antiviral activity, more specifically HIV (Human Immunodeficiency Virus) replication inhibiting properties. The invention also relates to methods for the preparation of such compounds, as well as to novel intermediates useful in one or more steps of such syntheses. The invention also relates to pharmaceutical compositions comprising an effective amount of such compounds as active ingredients. This invention further relates to the use of such compounds as medicines or in the manufacture of a medicament useful for the treatment of animals suffering from viral infections, in particular HIV infection. This invention further relates to methods for the treatment of viral infections in animals by the administration of a therapeutical amount of such compounds, optionally combined with one or more other drugs having antiviral activity.

  本发明涉及一系列具有抗病毒活性的新型化合物，更具体地说，是具有抑制HIV（人类免疫缺陷病毒）复制的特性。本发明还涉及制备这种化合物的方法，以及在这些合成步骤中有用的新型中间体。本发明还涉及包含有效量的这种化合物作为活性成分的制药组合物。此外，本发明还涉及使用这种化合物作为药物或制造有用于治疗患有病毒感染的动物，特别是HIV感染的药物。此外，本发明还涉及通过给动物施加治疗量的这种化合物，可选地与一种或多种其他具有抗病毒活性的药物结合，治疗动物病毒感染的方法。
• AUTOTAXIN INHIBITORS
  申请人：BEATTIE David

  公开号：US20160184318A1

  公开（公告）日：2016-06-30

  The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.

  本发明涉及新型的自体磷脂酰肌醇酰化酶抑制剂化合物，其制备方法，包含它们的药物组合物和药物以及它们在由自体磷脂酰肌醇酰化酶介导的疾病和障碍中的应用。
• Autotaxin inhibitors
  申请人：Novartis AG

  公开号：US10183025B2

  公开（公告）日：2019-01-22

  The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.

  本发明涉及作为自体舒缩素抑制剂的新型化合物、其制备工艺、含有它们的药物组合物和药品，以及它们在自体舒缩素介导的疾病和失调中的用途。